Presbyterian/St. Luke's Medical Center

The trials here

What the 5 trials at this site are about, from their registry records.

Conditions

• Myelodysplastic syndromes3 trials
• Acute myeloid leukaemia2 trials
• Chronic myeloid leukaemia1 trial
• Diffuse large B-cell lymphoma1 trial
• Melanoma1 trial

Phase

• Phase 33 trials
• Phase 11 trial
• Phase 21 trial

Status

• Completed3 trials
• Active, not recruiting1 trial
• Recruiting1 trial

Lead sponsor

• ECOG-ACRIN Cancer Research Group1 trial
• Institut de Recherches Internationales Servier1 trial
• Seagen, a wholly owned subsidiary of Pfizer1 trial
• SWOG Cancer Research Network1 trial
• Takeda1 trial

Running trials

• Recruiting

  Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation

  NCT06465953· Phase 3· Institut de Recherches Internationales Servier· Source

  Contact: Institut de Recherches Internationales Servier (I.R.I.S.), Clinical Studies Department

• Active, not recruiting

  A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

  NCT04227847· Phase 1· Seagen, a wholly owned subsidiary of Pfizer· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Myelodysplastic syndromes1 recruiting

Closed trials

• Completed

  Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)

  NCT03268954· Phase 3· Takeda· Source

• Completed

  S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma

  NCT01359592· Phase 2· SWOG Cancer Research Network· Source

• Completed

  High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

  NCT00003641· Phase 3· ECOG-ACRIN Cancer Research Group· Source